Clinical Trial

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-05-22; most recent amendment 2025-08-27.
Status change: Not Yet Recruiting → Recruiting 2023-10-03
Trial Details
NCT Number NCT05874401
Lead Sponsor Pharmacosmos A/S
Conditions Extensive-stage Small-cell Lung Cancer
Enrollment 302 participants
Start Date 2023-10-18
Primary Completion 2027-10-30 (estimated)
Study Completion 2027-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-04